Search results for "relap"

showing 10 items of 217 documents

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve …

2012

. In chronic hepatitis C (CHC), treatment duration may be individualized according to time to first undetectable hepatitis C virus (HCV) RNA, with patients who attain undetectable HCV RNA early in treatment being candidates for shorter regimens. The aim of this study was to determine the relapse rate in patients with CHC genotype (G) 1 infection and low baseline viral load who achieved undetectable HCV RNA by week 4 [rapid virologic response (RVR)] when treated for 24 weeks. This was an open-label, multicentre, noninterventional study. Adult patients with G1 CHC infection and baseline viral load <600,000 IU/mL who attained RVR were treated with peginterferon alfa-2b (1.5 mu g/kg/week) plus …

AdultMaleTime FactorsAdolescentGenotyperibavirinHepacivirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolsYoung AdultRecurrenceRibavirinHumanspeginterferonhepatitis C virus genotyperelapseInterferon-alphaHepatitis C ChronicMiddle AgedViral LoadRecombinant Proteinsviral loadTreatment OutcomeHCVFemale
researchProduct

Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.

2009

OBJECTIVE: Recent findings support greater efficacy of early vs. delayed interferon beta (IFNbeta) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFNbeta treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFNbeta treatment with regard to the greatest benefits on disability progression. METHODS: A cohort of 2,570 IFNbeta-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients wit…

AdultMaleTime FactorsMultiple Sclerosis; Interferon betaInterferon-beta.Interferon betaCohort StudiesYoung AdultMultiple Sclerosis Relapsing-RemittingTreatment Outcomeobservational study multiple sclerosis interferon treatment earlySickness Impact ProfileMultiple SclerosiQuality of LifeHumansFemaleSettore MED/26 - NeurologiaProspective StudiesFollow-Up Studies
researchProduct

Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis

2018

Abstract Background The number of white matter lesions (WML) in brain MRI is the most established paraclinical tool to support the diagnosis of multiple sclerosis (MS) and to monitor its course. Diagnostic criteria have stipulated a minimum detectable diameter of 3 mm per WML, although this threshold is not evidence-based. We aimed to provide a rationale for a WML size threshold for three-dimensional MRI sequences at 3 T by comparing patients with relapsing-remitting MS (RRMS) to control subjects (CS). Methods We analyzed MR images from two cohorts, obtained at scanners from two different vendors, each comprising patients with RRMS and CS. Both cohorts were examined with FLAIR and T1w seque…

AdultMaleWhite matter lesionNeuroimagingFluid-attenuated inversion recoveryYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineHumansMedicine030212 general & internal medicineRetrospective StudiesExpanded Disability Status ScaleReceiver operating characteristicbusiness.industryMultiple sclerosisGeneral MedicineOdds ratioReference Standardsmedicine.diseaseMagnetic Resonance ImagingWhite MatterHyperintensityNeurologyRelapsing remittingFemaleNeurology (clinical)businessNuclear medicine030217 neurology & neurosurgeryMultiple Sclerosis and Related Disorders
researchProduct

Gray matter integrity predicts white matter network reorganization in multiple sclerosis

2019

Abstract Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease leading to gray matter atrophy and brain network reconfiguration as a response to increasing tissue damage. We evaluated whether white matter network reconfiguration appears subsequently to gray matter damage, or whether the gray matter degenerates following alterations in white matter networks. MRI data from 83 patients with clinically isolated syndrome and early relapsing–remitting MS were acquired at two time points with a follow‐up after 1 year. White matter network integrity was assessed based on probabilistic tractography performed on diffusion‐weighted data using graph theoretical analyses. We ev…

AdultMalegraph theory610 MedizinneuropsychologytractographyBiologyNeuropsychological Testsmultiple sclerosisGray (unit)050105 experimental psychologyWhite matter03 medical and health sciences0302 clinical medicineAtrophyMultiple Sclerosis Relapsing-Remittingatrophy610 Medical sciencesmedicineHumans0501 psychology and cognitive sciencesRadiology Nuclear Medicine and imagingstructural connectivityGray Matternetwork analysisResearch ArticlesTemporal cortexCerebral CortexClinically isolated syndromeRadiological and Ultrasound TechnologyMultiple sclerosisPutamen05 social sciencesMiddle Agedmedicine.diseaseWhite Mattermedicine.anatomical_structureDiffusion Tensor ImagingNeurologyDisease ProgressionFemaleNeurology (clinical)AnatomyNerve NetNeuroscience030217 neurology & neurosurgeryTractographyResearch ArticleFollow-Up StudiesHuman Brain Mapping
researchProduct

The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis

2019

: Background: The role of the neutrophil-to-lymphocyte ratio (NLR) of peripheral blood has been investigated in relation to several autoimmune diseases. Limited studies have addressed the significance of the NLR in terms of being a marker of disease activity in multiple sclerosis (MS). Methods: This is a retrospective study in relapsing&ndash

AdultMalelymphocytesmedicine.medical_specialtyAdolescentlymphocyteLogistic regressionmultiple sclerosisArticleNLR; disease activity; lymphocytes; multiple sclerosis; neutrophilsNLRCohort StudiesDisease activityLeukocyte CountYoung AdultMultiple Sclerosis Relapsing-RemittingneutrophilsInternal medicinemedicineHumansNeutrophil to lymphocyte ratiolcsh:QH301-705.5Retrospective StudiesGenetic associationbusiness.industryMultiple sclerosisfungineutrophilRetrospective cohort studyGeneral MedicineMiddle AgedPrognosismedicine.diseaseRelapsing remittinglcsh:Biology (General)multiple sclerosiCohortDisease ProgressionFemalebusinessdisease activityBiomarkers
researchProduct

Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS

2020

ObjectiveTo investigate the association of serum neurofilament light chain (sNfL) levels with CSF parameters in clinically isolated syndrome (CIS) and early relapsing-remitting MS (RRMS), taking into account radiologic and clinical parameters of disease activity.MethodsSimultaneously collected serum and CSF samples of 112 untreated patients newly diagnosed with CIS or RRMS were included in this cross-sectional study. CSF parameters were obtained as part of routine diagnostic tests. sNfL levels of patients and of 62 healthy donors were measured by highly sensitive single molecule array (SiMoA) immunoassay.ResultsPatients with RRMS (n = 91, median 10.13 pg/mL, interquartile range [IQR] 6.67–1…

AdultMalemedicine.medical_specialty41LeukocytosisNeurofilament lightInflammationIntrathecalGastroenterologyArticleLeukocyte CountMultiple Sclerosis Relapsing-RemittingNeurofilament ProteinsInterquartile rangeInternal medicinemedicineHumansPleocytosisInflammationClinically isolated syndromemedicine.diagnostic_testbusiness.industryAxonsHighly sensitiveCross-Sectional StudiesNeurologyImmunoglobulin GImmunoassayFemaleNeurology (clinical)medicine.symptombusinessNeurology - Neuroimmunology Neuroinflammation
researchProduct

Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients.

2017

Background We conducted a retrospective single-center study to investigate the potential impact of cytomegalovirus (CMV) DNAemia on mortality in allogeneic stem cell transplant recipients (allo-SCT). Methods A total of 151 consecutive patients who underwent T-cell replete allo-SCT were included in the study. Patients with CMV DNAemia were treated pre-emptively with antivirals upon detection of plasma CMV DNA loads >1500 IU/mL. Results At least one episode of CMV DNAemia occurred in 109 (72.2%), and 67 of these patients (61.5%) required one or more courses of antiviral therapy. The cumulative incidence of 1-year overall and non-relapse mortality (NRM) was 28.5% (95% confidence interval [CI],…

AdultMalemedicine.medical_specialtyAdolescentCongenital cytomegalovirus infectionCytomegalovirus030230 surgeryAntiviral Agents03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineHumansTransplantation HomologousNonrelapse mortalityCumulative incidenceYoung adultAgedRetrospective StudiesTransplantationbusiness.industryHazard ratiovirus diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseConfidence intervalTransplant RecipientsSurgeryInfectious DiseasesSpainCytomegalovirus InfectionsDNA ViralFemaleStem cellbusiness030215 immunologyStem Cell TransplantationTransplant infectious disease : an official journal of the Transplantation Society
researchProduct

Texture analysis in susceptibility-weighted imaging may be useful to differentiate acute from chronic multiple sclerosis lesions.

2020

To evaluate the diagnostic performance of texture analysis (TA) applied on non-contrast-enhanced susceptibility-weighted imaging (SWI) to differentiate acute (enhancing) from chronic (non-enhancing) multiple sclerosis (MS) lesions. We analyzed 175 lesions from 58 patients with relapsing-remitting MS imaged on a 3.0 T MRI scanner and applied TA on T2-w and SWI images to extract texture features. We evaluated the presence or absence of lesion enhancement on T1-w post-contrast images and performed a computational statistical analysis to assess if there was any significant correlation between the texture features and the presence of lesion activity. ROC curves and leave-one-out cross-validation…

AdultMalemedicine.medical_specialtyAdolescentContrast Media030218 nuclear medicine & medical imagingLesion03 medical and health sciencesYoung Adult0302 clinical medicineMultiple Sclerosis Relapsing-RemittingImage Processing Computer-AssistedMedicineHumansMultiple sclerosiRadiology Nuclear Medicine and imagingDiagnosis Computer-AssistedLeast-Squares AnalysisNeuroradiologyAgedRetrospective Studiesmedicine.diagnostic_testReceiver operating characteristicbusiness.industryMultiple sclerosisUltrasoundReproducibility of ResultsMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance ImagingRegressionLogistic modelsContrast agentROC Curve030220 oncology & carcinogenesisArea Under CurveSusceptibility weighted imagingAcute DiseaseChronic DiseaseRegression AnalysisFemaleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessEuropean radiology
researchProduct

Clinical activity after fingolimod cessation: Disease reactivation or rebound?

2018

Background and purpose There is debate as to whether the apparent rebound after fingolimod discontinuation is related to the discontinuation itself or whether it is due to the natural course of highly active multiple sclerosis (MS). Our aim was to survey the prevalence of severe reactivation and rebound after discontinuation of fingolimod in a cohort of Italian patients with MS. Methods Patients with relapsing-remitting MS who were treated with fingolimod for at least 6 months and who stopped treatment for reasons that were unrelated to inefficacy were included in the analysis. Results A total of 100 patients who had discontinued fingolimod were included in the study. Fourteen patients (14%…

AdultMalemedicine.medical_specialtyAdolescentDiseaseCohort StudiesMultiple sclerosisImmunosuppressive AgentYoung Adult03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineRecurrenceInternal medicineHumansMedicine030212 general & internal medicineFingolimod; Multiple sclerosis; Reactivation; Rebound; Neurology; Neurology (clinical)Natural courseReboundFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseReactivationMagnetic Resonance ImagingFingolimodDiscontinuationItalyWithholding TreatmentNeurologymultiple sclerosiCohortFemaleNeurology (clinical)Cohort StudiebusinessImmunosuppressive Agents030217 neurology & neurosurgeryHumanmedicine.drug
researchProduct